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Background: We studied the influence of the ACE I/D and ACTN3 R577X polymorphisms (single or combined) on
lower-extremity function in older women in response to high-speed power training.
Methods: One hundred and thirty-nine healthy older Caucasian women participated in this study (age: 65.5 ± 8.2 years,
body mass: 67.0 ± 10.0 kg and height: 1.57 ± 0.06 m). Walking speed (S10) performance and functional capacity
assessed by the “get-up and go” (GUG) mobility test were measured at baseline (T1) and after a consecutive 12-week
period of high-speed power training (40-75% of one repetition maximum in arm and leg extensor exercises; 3 sets
4–12 reps, and two power exercises for upper and lower extremity). Genomic DNA was extracted from blood samples,
and genotyping analyses were performed by PCR methods. Genotype distributions between groups were compared
by Chi-Square test and the gains in physical performance were analyzed by two-way, repeated-measures ANOVA.
Results: There were no significant differences between genotype groups in men or women for adjusted baseline
phenotypes (P > 0.05). ACE I/D and ACTN3 polymorphisms showed a significant interaction genotype-training only in
S10 (P = 0.012 and P = 0.044, respectively) and not in the GUG test (P = 0.311 and P = 0.477, respectively). Analyses of
the combined effects between genotypes showed no other significant differences in all phenotypes (P < 0.05) at
baseline. However, in response to high-speed power training, a significant interaction on walking speed (P = 0.048)
was observed between the “power” (ACTN3 RR + RX & ACE DD) versus “non-power” muscularity-oriented genotypes
(ACTN3 XX & ACE II + ID)].
Conclusions: Thus, ACE I/D and ACTN3 R577X polymorphisms are likely candidates in the modulation of
exercise-related gait speed phenotype in older women but not a significant influence in mobility traits.
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The over-sixty year-old segment of the population ex-
hibits an increased susceptibility to mobility limitations
[1]. Aging also leads to a slowed capacity to develop high
velocity movements and perform physical tasks to main-
tain independent functioning [2-4]. Two systematic
reviews [1,5] reported that a slower walking speed is* Correspondence: mikel.izquierdo@gmail.com
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reproduction in any medium, provided the orpredictive of mobility limitations and a higher subse-
quent risk of fracture, institutionalization and mortality
[6,7]. In older populations, functional capacity declines
with advancing age, especially in older women [8], which
increases the importance of rehabilitation and preven-
tion programs to increase strength, mobility and balance
confidence.
Like any other type of therapeutic intervention, exercise-
training adaptations in older population are specific toLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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limbs, previous studies have reported relevant increases
in muscular power and functional capacity following
resistance-training programs of variable durations in older
women [8,11]. In addition, maximal strength and power in
individual limbs are strongly correlated with mobility in
older adults [12].
Improved knowledge of the specific mechanisms that
mediate impairments in physical functioning, especially
the relevance of functionality tests (gait speed versus
mobility), based on demonstration of strength and
muscle power, are crucial for developing effective inter-
ventions for preserving mobility and independence
among older people [8,12].
Molecular analysis in older people can offer the oppor-
tunity to assess nonconventional exercise and lifestyle
changes in an attempt to prevent muscular, metabolic or
cardiovascular diseases. Several studies in different pop-
ulations [13-18], [19,20] have confirmed that there is a
considerable genetic component to the trainability of ex-
ercise performance and functional muscle properties. In-
deed, multiple nuclear markers have been significantly
associated and genetically determined as indicators of
physical performance and muscular speed [10]. Accord-
ing to previous studies, both the angiotensin-converting
enzyme (ACE) I/D and alpha-actinin 3 (ACTN3) R/X
polymorphisms seem to be strong candidates to influ-
ence skeletal muscle phenotypes in older populations
[16,18,21]. In fact, we have recently observed an effect of
both ACE and ACTN3 genetic variants (individually or
in combination) on muscle power gains and functional
capacity in older Caucasian women in response to a
high-speed power training [21]. Hence, the aim of the
present study was to expand our previous results explor-
ing a parameter of gait speed (walking 10 m distance,
S10) and another mobility test (“go up and go” test,
GUG) essential in maintaining balance and preventing
falls in older populations. Both are components of pre-
dicted mobility limitations in the lower extremities and
are fundamental in reflecting muscle function in older
people [22].
To our knowledge, no association study exists that
addresses genetic variation in mobility tests. Our
current working hypothesis was focused on examining
the influence of the ACE I/D and ACTN3 polymor-
phisms, alone and in combination, on walking speed
and “get-up and go” test times in older Caucasian
women in response to a consecutive 12-week period of
high-speed power training stimuli. Thus, the purpose
of this study was to determine the association of the
combination of ACE I/D and ACTN3 R577X geno-
types with gait speed and mobility trait in older
women and to determine if the association of these
polymorphisms may partly explain the interindividualvariability in muscle function adaptation to resistance
training.
Methods
Experimental design and approach to the problem
The goal of the present study was to expand our previ-
ous results comparing the influence of the ACE I/D and
ACTN3 polymorphisms, alone and in combination, on
walking speed 10 m distance (S10) performance and
functional capacity as assessed by the “get-up and go”
test, walking 2.44 m, turning, and returning to seated
position (GUG) in older Caucasian women in response
to a consecutive 12-week period of high-speed power
training. A detailed description of the testing procedures
has been given elsewhere [8]. To test the stability and re-
liability of the performance variables, a given section of
the sample was consistently evaluated at the same time
and location and supervised by the same researchers at
pre- and post-intervention. Subjects were evaluated
twice before the start of training (weeks −2 and 0), and
this served as a control period (T1). In addition, we had
previously tested the stability and reliability of these var-
iables using a larger number of subjects over a control
period in older women [8]. The same tests were then ap-
plied after the 12-week experimental period (T2).
Subjects
One hundred thirty-nine healthy older Caucasian women
participated in this study (age: 65.5 ± 8.2 years, body mass:
67.0 ± 10.0 kg and height: 1.57 ± 0.06 m). None of the par-
ticipants had a history of strength training. The study sub-
jects underwent a resistance-training program comprising
three training sessions per week over 12 weeks based on
the program developed by Pereira and colleagues [21]. In-
clusion criteria for this group were: to be woman, older
and no history of strength training. Before inclusion in the
study, all candidates were thoroughly screened by a
physician. Exclusion criteria included metallic prosthesis
implants, artificial pacemakers, smoking habit, hip re-
placement surgery, walking only with assistance, and
metabolic or endocrine disorders known to affect the
musculoskeletal system. Each volunteer answered a face-
to-face questionnaire addressing medical history, hormone
replacement therapy, lifestyle habits, and medication use.
All participants were of the same Caucasian ancestry over
at least three generations. The experimental procedures
were approved following the Helsinki Declaration and
have been performed with the approval and Ethics Com-
mittee of Research Centre in Sports, Health and Human
Development, of the University of Trás-os-Montes and
Alto Douro, Department of Sport Sciences (reference
number 002/2012). Written informed consent was ob-
tained from each participant for the permission to use
their information for the present report.
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During fall 2010, blood was collected in regular filter
paper by finger blood spot (Albet, DP 400200), stored in
separate plastic bags at 4ºC until DNA extraction. Che-
lex 100® protocol (BioRad Laboratories, Hercules, CA)
was used to extract DNA [23]. We followed the ACE I/D
(rs1799752) and ACTN3 R577X (rs1815739) polymor-
phisms and were amplified by polymerase chain reaction
(PCR), and the resulting PCR products were genotyped
using agarose gel electrophoresis. The primers used
for the ACE I/D polymorphism were F-5′-CTGGAGA
CCACTCCCATCCTTTCT-3′ and R-5′-GATGTGGC
CATCACATTCGTCAGAT-3′. The ACE I/D fragments
without insertion (Dallele) and with insertion (I-allele)
of 190 and 490 bp, respectively, were detected on a 1.5%
agarose gel containing ethidium bromide. For ACTN3
R577X polymorphism genotyping, a fragment of 291 bp
was amplified with the following primers: ACTN3-F
5′-CTGTTGCCTGTGGTAAGTGGG-3′ and ACTN3-R
5′-TGGTCACAGTATGCAGGAGGG-3′. ACTN3 geno-
types were established by enzymatic digestion of ampli-
cons with Dde I. The R577X change creates a restriction
site resulting in fragments of 108, 97, and 86 bp. Digestion
of the R577 allele results in fragments of 205 and 86 bp,
and digestion of the 577X allele results in fragments of
108, 97, and 86 bp. The fragments were detected on a 3%
agarose gel containing ethidium bromide.
Phenotype assessment
Tests were applied at two intervals: before the start of
the 12-week experimental period (T1) and at its close
(T2). Before testing, subjects were familiarized with all
testing procedures, preceded by a general warm-up
routine.
Anthropometric measures: total height (m) and body
weight (kg) were assessed according to international
standards for anthropometric assessment. To evaluate
height a stadiometer (SECA, model 225, Germany) with
a range scale of 0.10 cm was used and body mass (kg)
was measured to the nearest 0.1 kg using a digital scale
(Philips, type HF 351/00).
Gait speed measure: was measured with subjects
instructed to perform three maximum effort sprints of
10 m (S10) beginning 2 m before the start line, in order
to achieve optimal velocities over the test distance. Time
at 0–10 m (S10) was recorded using Micrograte equip-
ment (Racetime2 Light Radio Kit, USA). Subjects per-
formed trial sprints, separated by 3 min of rest, on an
indoor rubberized track.
Mobility measure: was evaluated over a walking dis-
tance of 2.44 m, characterized by “get-up and go” test
(GUG). This test enables dynamic balance assessment,
represented by the total time required for the subjects to
rise from a seated position, walk eight feet (2.44 m), turnaround and return to a seated position. The test was
visually demonstrated in advance, and each subject was
allowed to practice it once than two test trials were
administered.
The test–retest reliability for S10 and GUG measure-
ments taken was performed; the intra-class correlation
coefficient (ICC) was always higher than 0.90.
High-speed power training protocol
The resistance program (RT) consisted of progressive
loads by 3 sets of 12 reps with a load of 40% of 1RM at
the outset of a predetermined 1-repetition maximum up
until 3 sets of 4 reps with load of 75% towards the end
of the 12-week period in 1RMLE and 1RMBP. For max-
imal strength, subjects also performed two explosive ex-
ercises for the upper and lower limbs [8]. All exercise
training finished with abdominal crunches and trunk
extensors. Sessions started and finished with general
flexibility exercises. Rest intervals of 2 minutes between
sets and 3 minutes between exercises were deployed.
Verbal encouragement was given to ensure maximal
contractions.
Statistical analysis
Standard statistical methods were used for the calcula-
tion of means and standard deviations. Differences in
the distributions of the ACE and ACTN3 genotypes
were examined using Pearson’s x2. For Hardy-Weinberg
equilibrium calculations, x2 statistic (one degree of free-
dom) was computed from the observed distribution of
genotypes and the distribution of genotypes expected
from applying the Hardy-Weinberg equilibrium assump-
tion to the observed allele frequencies in the population.
Parameters measured during exercise strength/power
testing and functional performance achieved at the be-
ginning and end of high-speed power training were ana-
lyzed by one-way ANOVA after checking for normality
by Kolmogorov-Smirnov and for homogeneity of vari-
ance by Levene’s test. The two-way repeated-measures
ANOVA, was used in each performance measure as the
within-subjects variable and ACE and ACTN3 genotype
as the between-subjects variable. Post hoc testing for sig-
nificant differences in the ANOVA was performed by
the Tukey’s honestly significant difference test. The com-
bined effect of ACE I/D and ACTN3 R577X polymor-
phisms on the study phenotypes by ANOVA was
analyzed using two genotype combinations, i.e. ACE DD
and ACTN3 RR + RX (which hypothetically might be
more suitable for power/hypertrophy-oriented exercise
tasks) versus ACE II + ID and ACTN3 XX group [21].
Test-retest reliabilities, as shown by ICC, ranged from
0.90 to 0.93 for all testing exercises. Statistical signifi-
cance was accepted at p ≤ 0.05 for all analysis. All data
was analyzed using SPSS 17.0.
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The Hardy-Weinberg equilibrium (P = 0.125 and P = 0.06,
respectively) and the distribution of allelic frequencies for
ACE I/D and ACTN3 R577X genotypes in our cohort
study were 0.56 and 0.44 for the D- and I-alleles, respect-
ively, and 0.60 and 0.43 for the R- and X-alleles, respect-
ively. At baseline (T1) and after the resistance training
(T2), no significant differences (P > 0.05) in either ACE or
ACTN3 genotypes were observed for anthropometric
measures [21,24].
Table 1 shows the ACE genotype influence on per-
formance gains. From pre- to post-training period, sub-
jects increased their muscle power output by maximal
velocity in S10 (ID: 10.9%; DD: 14.3% and II: 10.2%), as
well in functional capacity measured by means of the
GUG test (ID: 13.2%; DD: 9.6% and II: 7.5%). Indeed,
significant training effects (within subject) were noted
for both walking speed and the GUG test (P < 0.05). More-
over, despite the significant differences among genotypes
for both tests in T2 the effect of genotype on performance
gains were only significant for S10 (P = 0.012) and not for
the GUG test (P = 0.331).
Similar results are shown in Table 2, respecting ACTN3.
From pre- to post-training, subjects significantly increased
their muscle power output by maximal velocity in S10
(RX: 10.9%; RR: 14.3% and XX: 11.9%), as well as in func-
tional performance (RX: 11.3%; RR: 11.5% and XX: 7.5%).
Significant group × time interactions (P < 0.05) were ob-
served for ACTN3 R577X. Significant training × genotype
effects of the ACTN3 R577X polymorphism were also
observed in S10 (P = 0.044) but not for the GUG test
(P = 0.477).
The analyses of the combined effects between geno-
types ACTN3 RR + RX & ACE DD versus ACTN3 XX
& ACE II + ID did not show a significant difference
(P > 0.05) at baseline. However, after 12-weeks of high-








S10 (m/s) ID (n = 52) 5.5 ± 0.7 4.9 ± 0.6a
DD(n = 52) 5.6 ± 0.7 4.8 ± 0.6b
II (n = 35) 5.9 ± 0.8 5.3 ± 0.8
P* 0.060 0.006
GUG (sec.) ID 5.3 ± 0.9 4.6 ± 0.5
DD 5.2 ± 0.8 4.7 ± 0.7
II 5.3 ± 0.8 4.9 ± 0.7
P* 0.721 0.013
Legend: Values are mean ± SD; n, no. of subjects. Pre-training and post-training, bef
reported values were measured at maximum effort. *P values (P < 0.001) were comp
II; bP < 0.001, DD significantly different from II.speed (P = 0.048) though not in the GUG test (P = 0.318)
(Figures 1 and 2) were observed in combined ACE and
ACTN3 genotypes.
Discussion
This study was the first to examine the influence of the
ACE and ACTN3 genotypes on training-induced changes
in gait speed and mobility before and after a high-speed
power training period in older Caucasian women. A dis-
tinctive finding of the present study was the evidence
that ACE I/D and ACTN3 R577X polymorphisms, indi-
vidually or in combination, have a significant influence
on gait speed phenotype in older Caucasian women but
not a significant influence in mobility trait in response
to high-speed power training.
The large variability in training-induced adaptations
suggests that molecular mechanisms also govern the
major part of muscle variation in exercise [10,22,25].
Insights concerning the ACE I/D and ACTN3 R577X
polymorphisms’ influence on the modulation of exercise-
related phenotypes in adults are controversial. In the
past decade, some studies have shown a positive effect
[13,26] on older subjects, particularly in response to
resistance training. However, several other studies have
failed to support a positive association [25,27,28]. Our
study, besides contributing to the clarification of this
discrepancy in the literature, focused on the effects of
ACE and ACTN3 genotypes on training-induced changes
in lower-extremity function in older Caucasian women.
The present study also stated that according to lower
extremity performance is a common weakness in older
people [4] and our molecular analysis can improve
knowledge of the specific physiological mechanisms that
mediate impairments in physical functioning. Present
data shows that high-speed power training is an effect-
ive therapeutic intervention. ACE I/D and ACTN3
R577X polymorphisms seem to influence variations intest performance gains during training
Repeated measures 2-way ANOVA
Training effect
(within subjects) P values
Genotype effect
(between subjects) P values
0.001 0.012
0.001 0.311
ore (T1) and after (T2) 12-week of high-speed power training, respectively. All
uted by one-way and 2-way ANOVA. aP < 0.001, ID significantly different from
Table 2 Effect of ACTN3 genotype in older Caucasian women in test performance gains during training





T1 T2 Training effect
(within subjects) P value
Genotype effect
(between subjects) P valueх±σ х±σ
S10 (m/s) RX (n = 54) 5.5 ± 0.7 4.9 ± 0.6a 0.001 0.044
RR (n = 52) 5.6 ± 0.6 4.8 ± 0.6b
XX (n = 33) 5.9 ± 0.9 5.2 ± 0.9
P* 0.080 0.050
GUG (sec.) RX 5.3 ± 0.9 4.7 ± 0.7 0.001 0.477
RR 5.2 ± 0.8 4.6 ± 0.5
XX 5.3 ± 0.8 4.9 ± 0.7
P* 0.615 0.139
Legend: Values are mean ± SD; n, no. of subjects. Pre-training and post-training, before (T1) and after (T2) 12-week of high-speed power training, respectively. All
reported values were measured at maximum effort. *P values (P < 0.001) were computed by one-way and 2-way ANOVA. aP < 0.001, RX significantly different from
XX; bP < 0.001, RR significantly different from XX.
Figure 1 Walking velocity test at the beginning of the protocol
(T1) and after 12-weeks (T2). Data presented are mean ± SD.
*Significantly different (P≤ 0.05) between T1 and T2 weeks;
†Significant changes (P≤ 0.05) between the groups.
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ity and maintaining reaction time in power tasks such
as crossing the road or avoiding a fall. However, the re-
sults of our study failed to support any significant genetic
influence for either polymorphism (single or combined)
in balance and mobility skills as measured by GUG test
performance.
At baseline (T1) no differences were observed in S10
and the GUG test. Nevertheless, at post-intervention
(T2), significant differences between ACE I/D genotypes
were confirmed.
There was a significant interaction between ACE geno-
type and S10 after 12-weeks of high-speed power train-
ing in older women, with greater improvements in
velocity shown by subjects with the D allele (DD and ID
genotypes). However, as ACE II genotype has a lower
number of subjects, this might play some role in the
results.
As previously reported by Gordon et al. [29], ACE ca-
talyses the production of angiotensin II which mediates
the hypertrophic response via the AT-1 receptor. As re-
search over the past decade has shown, the ACE gene is
associated with optimal muscle function, particularly in
strength at high velocity [30] such as sprint time per-
formance [23,31-33]. According to this, our data showed
that individuals with ACE*ID and ACE*DD genotypes
presented values suggesting superiority in the power vel-
ocity test (S10) compared to those with the ACE*II
genotype, both before and after the training program.
However, owing to complex effects, ACE I/D genotype-
training interaction did not influence mobility capacity
as measured by the GUG test. On performing this ex-
periment, older women tend to focus on maintaining
balance in rising from the chair and may disregard high
velocity execution. Also might be that the posture con-
trol (i.e. sensorial system) play a major role in it. Never-
theless, the changes that occur in skeletal musclestructure and function with aging may partial explain for
the lack of a significant relationship between mobility
phenotypes and the ACE I/D polymorphisms.
Concerning to the ACTN3 R577X polymorphism, a
significant gene*training interaction was also evident
only in S10 and not in the GUG test. Other studies have
reported similar results regarding the association be-
tween the ACTN3 genotype and sprint performance in
populations of varied ethnicity, including European,
American, and Israeli athletes [14,34-36]. Because ACTN3
expression is limited to type II fibers, the measurement of
S10 might be the best phenotype for testing the influence
of the ACTN3 polymorphism over typical mobility mea-
sures. According to the physiological role of ACTN3 in
speed and contraction velocity, we hypothesized those
participants who were ACTN3 deficient (XX) would not
be as strong or produce as much instantaneous power re-
sponses to high-speed power training as would R-allele
carriers. At baseline, the women homozygous for the
ACTN3 mutant allele 577X (XX) showed lower velocity
in S10 and GUG tests compared to the other genotypes.
Figure 2 “Get-up and go” test at the beginning of the protocol
(T1) and after 12-weeks (T2). Data presented are mean ± SD.
*Significantly different (P≤ 0.05) between T1 and T2 weeks;
†Significant changes (P≤ 0.05) between the groups.
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homozygous for the wild type (RR) and heterozygous (RX)
demonstrated superior performance in both measures
compared with the homozygous XX. Indeed, velocity were
greatest for RR and least for RX or XX polymorphisms, in
the R577X genotype was observed in the present study.
As in previous reports [13,15,17,25] our results confirm
that alpha-actinin-3 deficiency appears to impair muscle
performance. Also, the lack of alpha-actinin-3 may indi-
cate faster decline in muscle function with increasing age
[19] and selective atrophy of type II muscle fibers in ad-
vanced age could attenuate any influence of the ACTN3
genotype on muscle function [26]. Moreover, as Clarkson
et al. [26] suggested, our study confirms that subjects lack-
ing in ACTN3 do not increase power as do those having
the 577R allele.
Norman et al. [37], as previously stated that repeated
exercise may show an increase in power performance in
RR, though not in XX genotypes, suggesting that the
ACTN3 genotype may modulate responsiveness to train-
ing in women [38,39]. It seems that α-actinin-3 expres-
sion may affect muscular capacity, which implies that
α-actinin-2 may compensate for this deficiency and
neutralize the phenotypic consequences at baseline
[13,25,39]. Indeed, our intervention program based on
high-speed actions was essential in revealing a signifi-
cant difference between ACTN3 genotypes on perform-
ance and response to training particular in older
women. It seems that only precise testing (i.e. maximal
strength, power) can demonstrate significant difference
between subjects, specifically after a program training
intervention.
Indeed, in older Caucasian women, the present data
showed that ACE II + ID & ACTN3 XX versus ACE DD &
ACTN3 RR + RX revealed significant differences (P < 0.05)
only in an S10 test evaluated after 12-weeks of high-speedpower training. A mean improvement of gait speed in sub-
jects with D and R alleles may correspond with meaningful
reductions in risk for these adverse outcomes. Concerning
the GUG test, it would appear that this is a consistent
measure for evaluating the prognosis of falls [40] but is not
sufficiently sensitive to absorb a significant genotype-
training interaction of both ACE I/D and ACTN3 R577X
polymorphisms (alone or in combination). Balance and co-
ordination skills are too complex to enable the isolation of
a restricted polymorphic influence. Future studies are also
necessary with larger samples of older males and young
people in order to replicate the findings we obtained with
our studies.
The present study has some limitations. First, our
participants were limited to older women, and do not
permit to study the influence of gender in genetic asso-
ciation with muscular phenotypes. Secondly, according
to muscle function, these measures should be analyzed
in older people with functional limitations to observe if the
training has the same effect in the present genotypes.
Conclusion
In summary, this study has shown that both ACE I/D
and ACTN3 R577X polymorphisms (alone or in com-
bination) are strong candidates in the modulation of
power phenotypes such as walking velocity in response
to high-speed power training in older Caucasian women.
In functional measures such as the “get-up and go” test
that does not focus on a restricted power contraction,
significant differences between genotypes are not easily
identified. Our study confirms the importance of analyz-
ing the effects of a 12 week intervention in gait speed
and mobility in older people.
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